Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd.

Explore bluebird bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for BLUE. Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $ ...

Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago. These figures ...

StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a report published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.

March 28 (Reuters) - Gene therapy maker bluebird bio (BLUE.O), opens new tab said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8 ...

Equities research analysts at StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE – Get Free Report) in a research report issued to clients and investors on Thursday.